Form 4 for JANX Janux Therapeutics, Inc.
Accepted 2024-12-20 00:00:00 ET · period of report 2024-12-19 · accession 0001415889-24-029989 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-12-20 | 2024-12-19 | JANX | Meyer Andrew Hollman | Chief Business Off | M - OptEx | $20.24 | +9,881 | 77.5K | +15% | +$200.0K |
| DM | 2024-12-20 | 2024-12-19 | JANX | Meyer Andrew Hollman | Chief Business Off | M - OptEx | $0.00 | -9,881 | 90.0K | -10% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-12-19 | M | A | 1 | $14.02 | 77,473 | D | — | — | |
| 2 | Common | Common Stock | 2024-12-19 | M | A | 9,880 | $20.24 | 77,472 | D | — | — | |
| 3 | Derivative | Stock Option (right to buy) | 2024-12-19 | M | D | 9,880 | $0.00 | 96,870 | D | $20.24 · — to 2032-01-02 | 9,880 Common Stock | (F1) 25% of the shares subject to the option vested on January 1, 2023 and the balance vests in equal monthly installments thereafter over a three year period. |
| 4 | Derivative | Stock Option (right to buy) | 2024-12-19 | M | D | 1 | $0.00 | 89,999 | D | $14.02 · — to 2033-01-02 | 1 Common Stock | (F2) 25% of the shares subject to the option vested on January 1, 2024 and the balance vests in equal monthly installments thereafter over a three year period. |